World Pulmonary Drug Delivery Technologies Market

World Pulmonary Drug Delivery Technologies Market

This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in Millions of US$. The specific product segments analyzed are Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Nebulizers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 55 companies including many key and niche players worldwide such as 3M Drug Delivery Systems Division, Akela Pharma Inc., Alkermes Inc., Aradigm Corporation, AstraZeneca Plc, Baxter Healthcare Corporation, Chiesi Farmaceutici SpA, Consort Medical Plc, Dey L.P., GlaxoSmithKline Plc, Graceway Pharmaceuticals, LLC, Nektar Therapeutics, Oriel Therapeutics Inc., Sepracor Inc., SkyePharma Plc, and Vectura Group Plc . Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

PULMONARY DRUG DELIVERY TECHNOLOGIES MCP-1244
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-2
Product Definitions and Scope of Study I-3
Metered Dose Inhalers (MDIs) I-3
Dry Powder Inhalers (DPIs) I-3
Nebulizers I-4


II. EXECUTIVE SUMMARY

1. Market Dynamics II-1
Market Overview II-1
Pulmonary Devices: Gaining Pace II-1
Market Highlights II-1
Primary Position of the U.S II-2
Pulmonary Drug Delivery: An Attractive Non-Invasive Option II-2
Chief Pulmonary Delivery Technologies II-3
Most Effective Route for Respiratory Syndromes II-3
Leading Inhalation Prescription Drugs Across All Segments II-4
The Attractiveness of Inhalers II-4
Choice of Drug Delivery System II-4
Inhalation Therapy: A Retrospection II-4
Pulmonary Drug Delivery - Market Snapshots II-5

2. Trends and Issues II-6
Market Snippets II-6
Focus of New Age Pulmonary Devices II-6
Dry Powder Inhalation: A Promising Technology II-6
Research Activities in Inhaled Drug Delivery II-7
Lung Versus Oropharyngeal Deposition: A Major Challenge II-7
Competitive Environment II-7
A Backdrop II-7
Market Leaders II-8
Table 1: World Market for Inhaled Drug Delivery Systems
(2004): Percentage Share Breakdown of Sales by Major Brands-
Flovent, Serevent, Pulmicort, Atrovent, Ventolin, and Others
(includes corresponding Graph/Chart) II-8
Industry Efforts II-8
Inefficient Use of Pulmonary Drug Delivery Systems II-9
MDIs II-9
Spacers II-9
Dry Powder Inhalers II-10
Issues Facing Various Inhalation Devices II-10
Jet Nebulizers II-10
MDIs II-10
DPIs II-10

3. Growth Drivers II-11
Growth Drivers in Pulmonary Drug Delivery II-11
Use of Nano Technology in Drug Delivery Products II-11
Other Growth Areas II-11
Table 2: World Market for Pulmonary Drug Delivery
Technologies (2000 & 2005): Percentage Share Breakdown of
Sales by Drug Category- Bronchodilators, Anti-Inflammatories,
Protein/Peptide Therapeutics, Combination, and Other Small
Molecule (includes corresponding Graph/Chart) II-11
Innovative Pulmonary Devices Shape Progress II-12
Pulmonary Insulin II-12
Alternative Drug Delivery Systems: A Review II-12
Market Size II-12
Inhaled Small Molecule Therapeutics II-13

4. Product Overview II-14
Definition of Pulmonary Drug Delivery System II-14
Pulmonary Drug Delivery Technologies: An Introduction II-14
An Overview of Key Features of Popular Inhalation Devices II-14
Product Segments II-15
A. Nebulizers II-15
Nebulizers: Key Devices for Bronchodilator Delivery II-15
Working Principle of a Nebulizer II-16
Use of UDMs in Nebulizers II-16
Types of Nebulizers II-16
Ultrasonic Nebulizers II-16
Device Components II-17
Gray Areas II-17
Benefits II-18
Limitations II-18
Pneumatic Nebulizers II-18
Breath-Actuated Nebulizers II-18
Continuous Nebulization II-18
Nebulizers for Specific Applications II-19
Active Venturi Nebulizers II-19
New Designs for Improved Nebulizer Performance II-19
Limitations of Nebulizers II-19
Nebulizers and MDIs II-20
B. Metered Dose Inhalers (MDIs) II-20
Working Principle of an MDI II-20
MDI Timeline II-21
CFC-Propellant based MDIs II-22
Ban on CFCs II-22
Use of Spacers in MDIs II-22
Benefits of Spacers II-22
Types of Spacers II-23
Issue of Electrostatic Charge in Spacers II-23
Suitability of Spacers II-23
Innovative Delivery Systems II-24
Cutting Edge Developments in MDIs II-24
Merits of pMDIs II-24
Limitations II-24
Issues MDIs II-25
MDIs & Future II-25
Supply of MDIs in Developing Nations II-25
C. Dry Powder Inhalers (DPIs) II-25
Inspiratory Flow Rate in DPIs II-26
DPIs to Create Significant Impact II-26
DPIs: Not Entirely a New Concept II-26
Working Principle of DPIs II-26
Deaggregation in Dry Powder Inhalers (DPIs) II-27
Types of DPIs II-27
Passive DPI II-27
Active DPI II-27
Single-dose DPIs II-27
Multi-dose DPIs II-27
Other Types II-28
Development Activities in DPI II-28
Cost Considerations II-28
Benefits of DPI II-28
Limitations II-29
Issues II-29
In a nutshell II-29
Suitability of DPIs II-29
Trends II-29
Growth Areas II-30
Comparison between MDI and DPI II-30
Other Types of Inhalers II-31
Single-Breath Liquid Based Systems II-31
Multi Drug Atomizers II-31
Liquid Sieving II-31
Unit Dose Single Breath Atomizer II-32
Side Effects of Inhalers II-32
Side Effects in Children II-32

5. An Overview of Pulmonary Conditions and Therapies II-33
Drug Delivery to the Lung: An Insight II-33
The Respiratory System II-33
Methods of Drug Delivery through Pulmonary Route II-33
Aerosols Systems II-34
Intratracheal instillation II-34
Insufflation II-34
Pulmonary Delivery Approaches II-34
Controlled Release II-35
Asthma and COPD II-35
Asthma: Primary Respiratory Syndrome II-35
Trigger Factors II-36
Magnitude of Disease II-36
Chronic Obstructive Pulmonary Disease II-36
Magnitude of Disease II-37
Treatment of Asthma and COPD II-37
Drug Medications for Treating Asthma and COPD II-37
Bronchodilators (Acute Reliever Drugs) II-37
Categories of Bronchodilators II-37
Beta-agonists II-37
Short acting beta-agonists II-37
Long acting beta-agonists II-38
Anti-cholinergics II-38
Methylxanthines II-38
Anti-Inflammatory Medication (Controllers or Preventers) II-38
Inhaled glucocorticosteroids (or inhaled steroids) II-39
Cromoglycate-like drugs II-39
Other Delivery Routes for Asthma and COPD Treatment II-39
Oral Route II-39
New Oral Therapies II-40
Injectable Option II-40
Significance of Relievers and Preventers II-40
Steroid MDIs and DPIs II-40
Benefits of Pulmonary Drug Delivery Systems II-41
Protein Absorption II-41
Convenience II-41
Bioavailability II-41
Applications of Pulmonary Technology II-41
Titration by Therapy II-41
Titration by Patient II-42
Dose Reproducibility II-42
High Bioavailability II-42
Types of Inhaler Devices II-42
Aerosol Inhalers II-42
Breath-Actuated Inhalers II-42
Factors Influencing Clinical Effectiveness of Inhalation Device II-43
Device Factors II-43
Patient Factors II-43
Drug Factors II-43

6. Regulatory Environment II-44
The Montreal Protocol II-44
FDA Bans the Use of CFC’s in Metered Dose Inhalers II-44
A Brief Overview of CFC-MDI Transition II-44
Freon Compounds II-45
HFC Emissions II-45
Table 3: Ozone Depletion and Global Warming Impact of Various
Propellants II-46
Reformulation of MDIs II-46
Suitable Non-CFCs II-46
Country-wise Variations in CFC Transition II-46
Preference for HFCs II-46
Issues in HFC Use II-46
HFC MDI Gaining Momentum II-47
HFC MDIs Commercialization II-47
Potential of HFC 227ea II-48

7. Product Developments II-49
Generex Biotechnology Corporation Receives Patent from Mexican
Institute of Industrial Property II-49
Spiriva® Ensures Relief to COPD Sufferers II-49
Alkermes and Eli Lilly Initiates Phase 3 Clinical Study on AIR® II-49
Sepracor Receives FDA Approval for Arformoterol Tartrate
Inhalation Solution II-50
Vectura Group Completes Phase-II Proof-of-Concept Study on VR040 II-50
Ventaira Conducts Pharmacokinetic Study on Fluticasone Propionate II-50
Exubera® Inhalation Powder Receives FDA and European
Commission Approval II-50
LAB International Completes Phase I Trial on LAB CGRP II-51
Xopenex HFA Receives FDA Approval II-51

8. Product Innovations/Introductions II-52
Consort Medical Releases Meter Dose Inhalers II-52
Trinity Chiesi Pharmaceuticals Introduces Fostair II-52
AstraZeneca Launches Symbicort® II-52
Dey, L.P Unveils Perforomist™ II-52
Next Safety Rolls Out Hi-Performance Drug Delivery Technology II-53
Bang & Olufsen Medicom Unveils Aspira™ II-53
Exaeris Launches MD Turbo™ II-53
Chiesi Farmaceutici Launches Clenil® Modulite® pMDI II-53
GlaxoSmithKline Develops a New Advair Drug Formulation II-53

9. Recent Industry Activity II-54
Sepracor Signs Agreement with Nycomed II-54
Kamada Enter into Strategic Pacts with Pari Pharma II-54
GlaxoSmithKline Ties-Up with Amira Pharmaceuticals II-54
BattellePharma Takes Over Ventaira Pharmaceuticals II-54
Eurand Takes Over SourceCF II-54
Aradigm Signs Agreement with Lung Rx for Developing AERx
Essence(R) Technology II-55
Vectura Inks Agreement with a European Company II-55
ZYFLO CR™ Obtains FDA Clearance II-55
SkyePharma Revises Agreement with Abott II-56
Alnylam Presents Scientific Progress of ALN-RSV01 II-56
Bayer HealthCare and Nektar Therapeutics to Develop NKTR- 061 II-56
Graceway Snaps Up 3M Pharmaceuticals II-56
Ventaira Pharmaceuticals Signs Agreement with Nypro II-57
Novartis Forms Strategic Alliance with Schering-Plough II-57
Aradigm Divests Intraject Subcutaneous Delivery Technology to
Zogenix II-57
Exaeris Inks Agreement with Teamm Pharmaceuticals II-57
XstalBio Signs License Agreement with Boehringer Ingelheim II-57
Alkermes Signs Agreement with Eli Lilly II-58
Vectura Signs Agreement with Boehringer Ingelheim to Develop
New Dry Powder Inhaler II-58
Vectura Signs Collaboration Agreement for Combination Asthma
Therapy II-58
Lab Pharma and Teikoku Seiyaku Sign Licensing Agreement II-58
Airpharma Enters into an Agreement with Bespak for Developing
Inhalation Device II-59
Eiffel Technologies Signs Agreement with MAP Pharmaceuticals II-59
Inyx Acquires Celltech Manufacturing Services Limited II-59
Nektar Therapeutics Acquires Aerogen, Inc II-59
Chiesi Farmaceutici S.p.A. Enters into a Pact with
NovartisPharma AG for Formoterol Modulite® HFA II-60
Respirics Receives 510(k) Clearance for MD Turbo(TM) Device II-60
Sanofi-Synthelabo Acquires Aventis II-60
SkyePharma Plc Enters into a Strategic Alliance with Vectura II-60
Bespak Plc Enters into an Agreement with Innovata Biomed II-61
Chiesi Enters into an Agreement with Trudell Medical
International II-61
SkyePharma Plc and AstraZeneca Announce Completion of Phase
III Trials of HFA-MDI Corticosteroid II-61
Medical Industries Pens Agreement with ALR Technologies II-61
Inyx Inc Forays into Dry Powder Inhalers Segment II-62
BattellePharma Renamed Ventaira II-62
Valois Purchases Rights to New Dry Powder Inhaler II-62

10. Focus on Select Players II-63
3M Drug Delivery Systems Division (USA) II-63
Akela Pharma Inc. (Canada) II-63
Alkermes Inc., (USA) II-63
Aradigm Corporation (USA) II-64
AstraZeneca Plc (UK) II-64
Baxter Healthcare Corporation (USA) II-64
Chiesi Farmaceutici SpA (Italy) II-65
Consort Medical Plc (UK) II-65
Dey L.P. (USA) II-66
GlaxoSmithKline Plc (UK) II-66
Graceway Pharmaceuticals, LLC (USA) II-67
Nektar Therapeutics (USA) II-67
Oriel Therapeutics Inc. (USA) II-67
Sepracor Inc. (USA) II-68
SkyePharma Plc (UK) II-68
Vectura Group Plc (UK) II-68

11. Global Market Perspective II-69
Table 4: World Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Geographic Region -
US, Canada, Japan, Europe, Asia Pacific (excluding Japan),
Latin America and Rest of the World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-69

Table 5: World Long-term Projections for Pulmonary Drug
Delivery Technologies by Geographic Region - US, Canada,
Japan, Europe, Asia Pacific (excluding Japan), Latin America
and Rest of the World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) II-70

Table 6: World 10-Year Perspective for Pulmonary Drug Delivery
Technologies by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia Pacific
(excluding Japan), Latin America and Rest of the World Markets
for Years 2003, 2008, and 2012 (includes corresponding
Graph/Chart) II-71

Table 7: World Recent Past, Current and Future Analysis for
Metered Dose Inhalers (MDIs) by Geographic Region - US,
Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin
America and Rest of the World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) II-72

Table 8: World Long-term Projections for Metered Dose Inhalers
(MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia
Pacific (excluding Japan), Latin America and Rest of the World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-73

Table 9: World 10-Year Perspective for Metered Dose Inhalers
(MDIs) by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia Pacific (excluding
Japan), Latin America and Rest of the World Markets for Years
2003, 2008, and 2012 (includes corresponding Graph/Chart) II-74

Table 10: World Recent Past, Current and Future Analysis for
Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada,
Japan, Europe, Asia Pacific (excluding Japan), Latin America
and Rest of the World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-75

Table 11: World Long-term Projections for Dry Powder Inhalers
(DPIs) by Geographic Region - US, Canada, Japan, Europe, Asia
Pacific (excluding Japan), Latin America and Rest of the World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-76

Table 12: World 10-Year Perspective for Dry Powder Inhalers
(DPIs) by Geographic Region - PercentageBreakdown of Dollar
Sales for US, Canada, Japan, Europe,Asia Pacific (excluding
Japan), Latin America andRest of the World Markets for Years
2003, 2008,and2012 (includes corresponding Graph/Chart) II-77

Table 13: World Recent Past, Current and Future Analysisfor
Nebulizers by Geographic Region - US, Canada, Japan, Europe,
Asia Pacific (excluding Japan), Latin America and Rest of the
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-78

Table 14: World Long-term Projections for Nebulizers by
Geographic Region - US, Canada, Japan, Europe, Asia Pacific
(excluding Japan), Latin America and Rest of the World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-79

Table 15: World 10-Year Perspective for Nebulizers by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia Pacific (excluding Japan),
Latin America and Rest of the World Markets for Years 2003,
2008, and 2012 (includes corresponding Graph/Chart) II-80


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Outlook III-1
Forecast for the Near Future III-1
Nebulizers: Engraving High Market Interests III-2
Table 16: US Market for Pulmonary Drug Delivery
Technologies (2000, 2005 & 2010): Percentage Share
Breakdown by Application Area - Asthma/COPD, Diabetes,
Cancer, Cystic Fibrosis, and Migraine (includes
corresponding Graph/Chart) III-2
New Age Pulmonary Drug Delivery Technologies III-2
Inhaled Prescription Drugs in the US: Ranking of Flovent
(fluticasone), Serevent (salmeterol), Pulmicort Turbohaler
(budesonide), Atrovent (ipratropium bromide), Ventolin
(albuterol), Combivent (ipratropium bromide + albuterol
sulfate), and Advair/Seretide (fluticasone +
salmeterol) III-3
Role of FDA III-3
Metered Dose Inhalers III-3
Non-CFC Metered Dose Inhalers III-3
Table 17: U.S Market for Non-CFC Metered Dose Inhalers
(2000, 2005 & 2010): Percentage Share Breakdown by
Application Areas- Asthma/ COPD and Cancer III-3

Table 18: Primary Manufacturers of Non-CFC Metered Dose
Inhalers in the U.S (2004): Percentage Share Breakdown by
3M Drug Delivery Systems and GlaxoSmithKline III-4
Dry Powder Inhalers III-4
Table 19: US Market for Dry Powder Inhalers (2004):
Percentage Share Breakdown of Value Sales by Major
Players-GlaxoSmithKline, AstraZeneca and Novartis/
Schering- Plough (includes corresponding Graph/Chart) III-4
Popular DPIs in the U.S III-4
Trends in DPI Devices III-5
Table 20: US Market for Dry Powder Inhalers (2000, 2005, &
2010): Percentage Share Breakdown by Application Areas-
Asthma/COPD, Diabetes, Cystic Fibrosis, Cancer, and
Migraine (includes corresponding Graph/Chart) III-5
Drug Delivery Market in the U.S III-5
Competitive Landscape III-6
Product Launches/Developments III-6
Strategic Corporate Developments III-7
Select Players III-11
B.Market Analytics III-14
Table 21: US Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and
Nebulizers Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-14

Table 22: US Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-15

Table 23: US 10-Year Perspective for Pulmonary Drug Delivery
Technologies by Product Segment - Percentage Breakdown of
Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder
Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and
2012 (includes corresponding Graph/Chart) III-15

2. Canada III-16
A.Market Analysis III-16
Outlook III-16
Akela Pharma Inc. - A Major Player III-16
B.Market Analytics III-17
Table 24: Canadian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment
- Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Nebulizers Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-17

Table 25: Canadian Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-17

Table 26: Canadian 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-18

3. Japan III-19
A.Market Analysis III-19
Outlook III-19
Market Overview III-19
Table 27: Japanese Market for Pulmonary Drug Delivery
Systems (2004): Percentage Share Breakdown of Sales by
Leading Brands-Atrovent, Beclovent, Ventolin, Serevent,
Pulmicort, Flonase, and Others (includes corresponding
Graph/Chart) III-19
Market Highlights III-19
Strategic Corporate Developments III-20
Omron Healthcare Co. Ltd - A Major Player III-20
B.Market Analytics III-21
Table 28: Japanese Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment
- Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Nebulizers Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-21

Table 29: Japanese Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-21

Table 30: Japanese 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-22

4. Europe III-23
A.Market Analysis III-23
Outlook III-23
Transition to Non-CFC MDIs III-23
Potential Hurdles in DPI Penetration in Europe III-23
Market Awareness III-24
Price Issues III-24
Healthcare Effects III-24
Patient Retraining III-24
Strategic Corporate Development III-24
B.Market Analytics III-25
Table 31: European Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Geographic
Region - France, Germany, UK, Italy, Spain, Russia and Rest
of Europe Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-25

Table 32: European Long-term Projections for Pulmonary Drug
Delivery Technologies by Geographic Region - France,
Germany, UK, Italy, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015(includes corresponding
Graph/Chart) III-26

Table 33: European 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Geographic Region - Percentage
Breakdown of Dollar Sales for France, Germany, UK, Italy,
Spain, Russia and Rest of Europe Markets for Years 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-27

Table 34: European Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment
- Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Nebulizers Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-28

Table 35: European Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-29

Table 36: European 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-29

4a. France III-30
A.Market Analysis III-30
Outlook III-30
Market Overview III-30
Strategic Corporate Developments III-30
B.Market Analytics III-31
Table 37: French Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment
- Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Nebulizers Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-31

Table 38: French Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-31

Table 39: French 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-32

4b. Germany III-33
Market Analysis III-33
Table 40: German Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment
- Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Nebulizers Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-33

Table 41: German Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-34

Table 42: German 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-34

4c. The United Kingdom III-35
A.Market Analysis III-35
Outlook III-35
Market Overview III-35
Table 43: UK Market for Inhaled Drug Delivery Systems
(2004): Percentage Share Breakdown of Sales by Major
Brands- Serevent, Ventolin, Pulmicort, Flovent, Beclovent,
Atrovent, Flonase, Vancenase Pocket, Vancenase, and Other
(includes corresponding Graph/Chart) III-35
Areas of Growth III-35
Progress in Drug Delivery III-36
Asthma Incidence among Children III-36
Product Launches/Developments III-36
Strategic Corporate Developments III-37
Select Players III-41
B.Market Analytics III-43
Table 44: UK Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and
Nebulizers Markets Independently Analyzedwith Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-43

Table 45: UK Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-43

Table 46: UK 10-Year Perspective for Pulmonary Drug Delivery
Technologies by Product Segment - Percentage Breakdown of
Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder
Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and
2012 (includes corresponding Graph/Chart) III-44

4d. Italy III-45
A.Market Analysis III-45
Outlook III-45
Competitive Landscape III-45
Table 47: Italian Market for Pulmonary Drug Delivery
Systems (2004): Percentage Share Breakdown of Sales by
Major Brands- Pulmicort, Ventolin, Beclovent, Flovent,
Serevent, Atrovent, Flonase, Vancenase Pocket, Vancenase,
and Other (includescorresponding Graph/Chart) III-45
Strategic Corporate Developments III-46
Chiesi Farmaceutici SpA - A Major Italian Player III-46
B.Market Analytics III-47
Table 48: Italian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment
- Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Nebulizers Markets Independently Analyzed with Annual
Sales Figures in US$ Million forYears 2000 through 2010
(includes corresponding Graph/Chart) III-47

Table 49: Italian Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-48

Table 50: Italian 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-48

4e. Spain III-49
A.Market Analysis III-49
Outlook III-49
Competitive Landscape III-49
Table 51: Spanish Market for Pulmonary Drug Delivery
Systems (2004): Percentage Share Breakdown of Sales by
Leading Brands- Pulmicort, Beclovent, Serevent, Ventolin,
Atrovent, Flonase, Flovent, Vancenase Pocket, and Others
(includes corresponding Graph/Chart) III-49
B.Market Analytics III-50
Table 52: Spanish Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment
- Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Nebulizers Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-50

Table 53: Spanish Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015(includes
corresponding Graph/Chart) III-50

Table 54: Spanish 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-51

4f. Russia III-52
Market Analysis III-52
Table 55: Russian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment
- Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Nebulizers Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-52

Table 56: Russian Long-term Projections for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015(includes
corresponding Graph/Chart) III-53

Table 57: Russian 10-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-53

4g. Rest of Europe III-54
A.Market Analysis III-54
Outlook III-54
Ireland III-54
Growth of Systemic Drug Delivery Device Market in Chaos III-54
Sweden III-54
Prominent Position in DPIs III-54
The Netherlands III-54
Product Launch III-55
Strategic Corporate Development III-55
B.Market Analytics III-56
Table 58: Rest of Europe Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Nebulizers Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-56

Table 59: Rest of Europe Long-term Projections for Pulmonary
Drug Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-57

Table 60: Rest of Europe 10-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-57

5. Asia-Pacific III-58
A.Market Analysis III-58
Outlook III-58
China III-58
Market Scenario III-58
India III-58
Market Scenario III-58
Dry Powder Inhalers for Children III-58
Device Prices III-59
Australia III-59
Asthma: The Most Common Chronic Suffering Among Australians III-59
Australia Finding Preventives for Asthma Cure III-59
Use of CFCs in Australia III-59
B.Market Analytics III-60
Table 61: Asia Pacific Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Nebulizers Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-60

Table 62: Asia Pacific Long-term Projections for Pulmonary
Drug Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015(includes
corresponding Graph/Chart) III-61

Table 63: Asia Pacific 10-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,
2008, and 2012 (includes corresponding Graph/Chart) III-61

6. Latin America III-62
A.Market Analysis III-62
Outlook III-62
Brazil III-62
B.Market Analytics III-62
Table 64: Latin America Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Nebulizers Markets Independently Analyzed with
Annual Sales Figures inUS$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-62

Table 65: Latin America Long-term Projections for Pulmonary
Drug Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-63

Table 66: Latin America 10-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Salesfor Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Nebulizers Markets for
2003,2008 and 2012 (includes correspondingGraph/Chart) III-63

7. Rest of World III-64
Market Analysis III-64
Table 67: Rest of the World Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered DoseInhalers (MDIs), Dry Powder Inhalers
(DPIs) and Nebulizers Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-64

Table 68: Rest of the World Long-term Projections for
Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and
Nebulizers Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-65

Table 69: Rest of the World 10-Year Perspective for
Pulmonary Drug Delivery Technologies by Product Segment -
Percentage Breakdown of Dollar Sales for Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers
Markets for 2003, 2008 and 2012 (includes corresponding
Graph/Chart) III-65


IV. COMPETITIVE LANDSCAPE